BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abel S, Hasan S, Horne ZD, Colonias A, Wegner RE. Stereotactic body radiation therapy in early-stage NSCLC: historical review, contemporary evidence and future implications. Lung Cancer Manag 2019;8:LMT09. [PMID: 31044018 DOI: 10.2217/lmt-2018-0013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Ritter A, Quartermaine C, Pierre-Charles J, Balasubramanian S, Raeisi-Giglou P, Addison D, Miller E. Cardiotoxicity of Anti-Cancer Radiation Therapy: a Focus on Heart Failure. Curr Heart Fail Rep 2023. [PMID: 36692820 DOI: 10.1007/s11897-023-00587-0] [Reference Citation Analysis]
2 Saglam Y, Selek U, Bolukbasi Y. A novel and clinically useful weight-optimized dynamic conformal arc in stereotactic radiation therapy of non-small cell lung cancer: Dosimetric comparison of treatment plans with volumetric‐modulated arc therapy. Radiation Physics and Chemistry 2022. [DOI: 10.1016/j.radphyschem.2022.110623] [Reference Citation Analysis]
3 Arruda GV, Lourenção M, de Oliveira JHC, Galendi JSC, Jacinto AA. Cost-effectiveness of stereotactic body radiotherapy versus conventional radiotherapy for the treatment of surgically ineligible stage I non-small cell lung cancer in the Brazilian public health system. The Lancet Regional Health - Americas 2022;14:100329. [DOI: 10.1016/j.lana.2022.100329] [Reference Citation Analysis]
4 Lobb E, Plypoo A. Limits for the therapeutic application of the analytical anisotropic algorithm in the context of ablative lung radiotherapy near the minima of lung density and tumor size. J Appl Clin Med Phys 2022;:e13634. [PMID: 35533238 DOI: 10.1002/acm2.13634] [Reference Citation Analysis]
5 Wang Z, Kim J, Zhang P, Galvan Achi JM, Jiang Y, Rong L. Current therapy and development of therapeutic agents for lung cancer. Cell Insight 2022;1:100015. [DOI: 10.1016/j.cellin.2022.100015] [Reference Citation Analysis]
6 Molls M, Dapper H, Specht H. The Future of Cancer Therapy with X-rays: Patient Numbers, Innovations, Clinical Trials, and the Problem of Generating Evidence. Strategies for Sustainability of the Earth System 2022. [DOI: 10.1007/978-3-030-74458-8_20] [Reference Citation Analysis]
7 Cilleruelo-Ramos A, Cladellas-Gutiérrez E, de la Pinta C, Quintana-Cortés L, Sosa-Fajardo P, Couñago F, Mielgo-Rubio X, Trujillo-Reyes JC. Advances and controversies in the management of early stage non-small cell lung cancer. World J Clin Oncol 2021; 12(12): 1089-1100 [DOI: 10.5306/wjco.v12.i12.1089] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Chen H, Liu L, Wang H, Shao Y, Gu H, Duan Y, Feng A, Huang Y, Xu Z. Influence of Clinical and Tumor Factors on Interfraction Setup Errors With Rotation Correction for Vacuum Cushion in Lung Stereotactic Body Radiation Therapy. Front Oncol 2021;11:734709. [PMID: 34745956 DOI: 10.3389/fonc.2021.734709] [Reference Citation Analysis]
9 Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US. JAMA Oncol 2021. [PMID: 34673888 DOI: 10.1001/jamaoncol.2021.4932] [Cited by in Crossref: 24] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
10 Dupic G, Biau J, Molnar I, Chassin V, Dedieu V, Lapeyre M, Bellière-Calandry A. Significant Correlation Between Overall Survival and Mean Lung Dose in Lung Stereotactic Body Radiation Therapy (SBRT). Front Oncol 2020;10:1577. [PMID: 32850462 DOI: 10.3389/fonc.2020.01577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
11 Gordon K. Welcome to Volume 9 of Lung Cancer Management. Lung Cancer Manag 2020;9:LMT27. [PMID: 32256711 DOI: 10.2217/lmt-2020-0007] [Reference Citation Analysis]
12 Zhao Y, Khawandanh E, Thomas S, Zhang S, Dunne EM, Liu M, Schellenberg D. Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors. Radiat Oncol 2020;15:61. [PMID: 32106868 DOI: 10.1186/s13014-020-01491-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
13 Uzel EK, Figen M, Uzel Ö. Radiotherapy in Lung Cancer: Current and Future Role. Sisli Etfal Hastan Tip Bul 2019;53:353-60. [PMID: 32377108 DOI: 10.14744/SEMB.2019.25991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
14 Franceschini D, Cozzi L, De Rose F, Navarria P, Fogliata A, Franzese C, Pezzulla D, Tomatis S, Reggiori G, Scorsetti M. A radiomic approach to predicting nodal relapse and disease-specific survival in patients treated with stereotactic body radiation therapy for early-stage non-small cell lung cancer. Strahlenther Onkol 2020;196:922-31. [PMID: 31722061 DOI: 10.1007/s00066-019-01542-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]